TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01186887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
Study: NCT01795976
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 60mg/kg/day day -7 and day -6
Study: NCT02656394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical gel
Study: NCT00479102
Drug: Ferripel-3 - iron polysaccharide complex for prevention
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01760616
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Study: NCT00475085
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00343005
Drug: AMA1-C1/alhydrogel Malaria Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02453750
Drug: Hypersaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
Study: NCT03974932
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-acting local anesthetic. Dose 1.
Study: NCT03974932
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID.
Study: NCT03974932
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic.
Study: NCT03974932
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAID.
Study: NCT03974932
Drug: +/- Bupivacaine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic.
Study: NCT03974932
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-acting local anesthetic. Dose 2.
Study: NCT01900522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITI-214 Matching Placebo Oral Solution
Study: NCT05107063
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
Study: NCT03950544
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline and meropenem
Study: NCT01905943
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
Study: NCT04542135
Drug: Sulindac Pill
Normalized name: sulindac Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive either 150 mg oral sulindac twice daily.
Study: NCT04542135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills twice daily
Study: NCT00416494
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
Study: NCT00416494
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
Study: NCT00275561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler swallowed twice a day for 6 weeks
Study: NCT00193011
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT00193011
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT02520635
Drug: supra-early TEMODAL® chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02520635
Drug: standard TEMODAL® chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03203811
Drug: HTI-2088
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 dose levels
Study: NCT03203811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablet
Study: NCT02294344
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study.
Study: NCT03642717
Drug: JARDIANCE DUO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin and metformin
Study: NCT02609334
Drug: CRD007
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose given 3 hours prior to Mannitol challenge
Study: NCT00665977
Drug: Thermosmart & placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
Study: NCT00665977
Drug: Placebo Device & Nasacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
Study: NCT00648596
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Study: NCT03394781
Drug: DUR-928
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension daily for 28 days
Study: NCT02297815
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
Study: NCT02297815
Drug: Narrow-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, Penicillin
Study: NCT00699556
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
Study: NCT02299557
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied intra-anally once daily
Study: NCT01144624
Drug: AZD9773
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
Study: NCT01144624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of a saline solution
Study: NCT01434901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
Study: NCT00575055
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Study: NCT03333928
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 tablets, 250 mg
Study: NCT03333928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets manufactured to mimic HTD1801 tablets
Study: NCT01282255
Drug: NNC109-0012
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
Study: NCT01282255
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
Study: NCT01384565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study: NCT02205190
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02205190
Drug: Fimasartan/Rosuvastatin combination
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03650413
Drug: UTTR1147A
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTTR1147A will be administered based on disease status, as described in the protocol.
Study: NCT04136548
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study: NCT02220244
Drug: MD1003 100mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03272477
Drug: Perjeta Injectable Product
Normalized name: Perjeta Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Study: NCT01579058
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 4 years
Study: NCT01709110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC.
Study: NCT01709110
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01475643
Drug: Prednisolones acetate
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
Study: NCT02229422
Drug: GA101/HDMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.
Study: NCT03770208
Drug: Control: Standard Care + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
Study: NCT04227275
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study: NCT02105610
Drug: total intravenous anesthetics
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03632187
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo every week during 3 months
Study: NCT00049439
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04014257
Drug: NOV1601(CHC2014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
Study: NCT03391830
Drug: Atorvastatin-Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
Study: NCT03391830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00903617
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg for 8 weeks
Study: NCT00903617
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg for 8 weeks
Study: NCT00903617
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg for 8 weeks
Study: NCT00903617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 8 weeks
Study: NCT00903617
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: x mg for 8 weeks based from data from Part A
Study: NCT00903617
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: optional dose based on data from Part A
Study: NCT03752307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
Study: NCT03752307
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
Study: NCT02120781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
Study: NCT00485758
Drug: Comparator : placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin/laropiprant Placebo
Study: NCT03198091
Drug: Dun Ye Guan Xin Ning
Normalized name: Scrophularia ningpoensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
Study: NCT02676674
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Study: NCT02676674
Drug: Dose 2
Normalized name: Fluzone High-Dose 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Study: NCT04283955
Drug: High-dose MTX based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
Study: NCT03367403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03367403
Drug: LY3202626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01243008
Drug: Application of SHB001
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas
Study: NCT02934841
Drug: sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01377909
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily statin orally for 48 weeks
Study: NCT00985608
Drug: Group A: NCA 600 mg+antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
Study: NCT00985608
Drug: Group B: antibiotic treatment (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
Study: NCT01822899
Drug: Placebo ACCUHALER/DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
Study: NCT01822899
Drug: Placebo NDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
Study: NCT01268046
Drug: Estradiol oral capsule
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 oral capsule (1 mg estradiol) administered daily for one month
Study: NCT01268046
Drug: trasdermal placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal placebo patch with patch change every 84 hr for one month
Study: NCT01268046
Drug: placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral capsule administered daily for one month.
Study: NCT01574820
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet for 6 months
Study: NCT00005987
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02206425
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study: NCT02206425
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Study: NCT02229825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT04220372
Drug: Tongxinluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
Study: NCT04220372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
Study: NCT00758069
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, QD, taken orally for 4 weeks
Study: NCT00740441
Drug: AS1411
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
Study: NCT03726658
Drug: AGN-241751
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-241751 is supplied in tablet form
Study: NCT03726658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied in tablet form
Study: NCT00635349
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
Study: NCT00635349
Drug: Tramadol Hydrochloride Plus Acetaminophen
Normalized name: acetaminophen / tramadol hydrochloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
Study: NCT02579421
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00158249
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched for physical appearance
Study: NCT03283202
Drug: Cyclophosphamide 750mg/m2 by IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles